Steelhead Partners’s Medicines Co MDCO Stock Holding History

Steelhead Partners’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-13,800	Closed	-$464K	–	66
2016 Q2	$464K	Buy	+13,800	New	+$487K	0.05%	50

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Steelhead Partners's MDCO Position: Q3 2016 in Review

Steelhead Partners sold out of Medicines Co (MDCO) in Q3 2016, closing a stake of 13,800 shares — an estimated $464K sold.

Steelhead Partners first reported a position in MDCO in Q2 2016 and held it in 1 quarter. The position peaked at $464K in Q2 2016. 201 funds tracked by Wall St. Rank hold MDCO as of Q3 2016.

Steelhead Partners reported no remaining Medicines Co position as of Q3 2016 after selling out during the quarter.
Steelhead Partners sold 13,800 Medicines Co shares in Q3 2016, an estimated $464K.
Steelhead Partners first reported a position in Medicines Co in Q2 2016 and held it in 1 quarter.
Steelhead Partners's Medicines Co position peaked at $464K in Q2 2016.
201 funds tracked by Wall St. Rank held Medicines Co as of Q3 2016.

Based on Steelhead Partners's 13F filing for Q3 2016, filed 14 Nov 2016.